Sarepta Therapeutics
SRPT
318 hedge funds and large institutions have $7.9B invested in Sarepta Therapeutics in 2018 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 74 increasing their positions, 124 reducing their positions, and 38 closing their positions.
132% more first-time investments, than exits
New positions opened: 88 | Existing positions closed: 38
117% more funds holding in top 10
Funds holding in top 10: 6 → 13 (+7)
88% more capital invested
Capital invested by funds: $4.2B → $7.9B (+$3.69B)
18% more funds holding
Funds holding: 269 → 318 (+49)
4.14% more ownership
Funds ownership: 87.36% → 91.5% (+4.1%)
9% more call options, than puts
Call options by funds: $349M | Put options by funds: $322M
40% less repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 124
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$104M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$101M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$90.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$90.2M |
| 5 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$130M |
| 2 |
State Street
Boston,
Massachusetts
|
-$71.8M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
-$56.2M |
| 4 |
JP Morgan Chase
New York
|
-$47.9M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$39.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SWP
351
Stratos Wealth Partners
Beachwood,
Ohio
| – | -$37K | -500 | Closed |
|
|
APA
352
American Portfolios Advisors
Holbrook,
New York
| – | -$25.9K | -350 | Closed |
|
353
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$20K | -275 | Closed |
|
354
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$11K | -152 | Closed |
|
|
APP
355
Avantax Planning Partners
Dubuque,
Iowa
| – | -$7K | -99 | Closed |
|
|
ML
356
McAdam LLC
Philadelphia,
Pennsylvania
| – | -$6K | -80 | Closed |
|
SRPT Hedge Fund Activity: Q2 2018 in Review
318 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2018, worth a combined $7.9B — up 88% from $4.2B a quarter earlier.
Buyers outnumbered sellers: 88 funds opened new SRPT positions and 38 closed out — a net gain of 50 holders — while 74 added to existing stakes and 124 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $104M. The largest seller was BlackRock, cutting an estimated $130M.
- 318 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2018, up from 269 in Q1 2018.
- Funds reported $7.9B of Sarepta Therapeutics stock for Q2 2018, up 88% quarter-over-quarter.
- 88 funds opened new Sarepta Therapeutics positions in Q2 2018 and 38 closed out, a net change of +50 holders.
- The largest Sarepta Therapeutics buyer in Q2 2018 was T. Rowe Price Associates, an estimated $104M added.
- The largest Sarepta Therapeutics seller in Q2 2018 was BlackRock, an estimated $130M sold.
Based on aggregated 13F filings for Q2 2018.